iAB-RBC-283: A proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states by Bordbar, Aarash et al.
RESEARCH ARTICLE Open Access
iAB-RBC-283: A proteomically derived knowledge-
base of erythrocyte metabolism that can be
used to simulate its physiological and
patho-physiological states
Aarash Bordbar, Neema Jamshidi and Bernhard O Palsson
*
Abstract
Background: The development of high-throughput technologies capable of whole cell measurements of genes,
proteins, and metabolites has led to the emergence of systems biology. Integrated analysis of the resulting omic
data sets has proved to be hard to achieve. Metabolic network reconstructions enable complex relationships
amongst molecular components to be represented formally in a biologically relevant manner while respecting
physical constraints. In silico models derived from such reconstructions can then be queried or interrogated
through mathematical simulations. Proteomic profiling studies of the mature human erythrocyte have shown more
proteins present related to metabolic function than previously thought; however the significance and the causal
consequences of these findings have not been explored.
Results: Erythrocyte proteomic data was used to reconstruct the most expansive description of erythrocyte
metabolism to date, following extensive manual curation, assessment of the literature, and functional testing. The
reconstruction contains 281 enzymes representing functions from glycolysis to cofactor and amino acid
metabolism. Such a comprehensive view of erythrocyte metabolism implicates the erythrocyte as a potential
biomarker for different diseases as well as a ‘cell-based’ drug-screening tool. The analysis shows that 94 erythrocyte
enzymes are implicated in morbid single nucleotide polymorphisms, representing 142 pathologies. In addition,
over 230 FDA-approved and experimental pharmaceuticals have enzymatic targets in the erythrocyte.
Conclusion: The advancement of proteomic technologies and increased generation of high-throughput proteomic
data have created the need for a means to analyze these data in a coherent manner. Network reconstructions
provide a systematic means to integrate and analyze proteomic data in a biologically meaning manner. Analysis of
the red cell proteome has revealed an unexpected level of complexity in the functional capabilities of human
erythrocyte metabolism.
Background
The advancement of high-throughput data generation
has ushered a new era of “omic” sciences. Whole-cell
measurements can elucidate the genome sequence
(genomics) as well as detect mRNA (transcriptomics),
proteins (proteomics), and small metabolites (metabolo-
mics) under a specific condition. Though these methods
provide a broad coverage in determining cellular
activities, little integrated functional analysis has been
performed to date.
Genome-scale network reconstructions are a common
denominator for computational analysis in systems biol-
ogy as well as an integrative platform for experimental
data analysis [1,2]. There are several applications of
reconstructions including: 1) contextualization of high-
throughput data, 2) directing hypothesis-driven discov-
ery, and 3) network property discovery [1]. Network
reconstruction involves elucidating all the known bio-
chemical transformations in a particular cell or organ-
ism and formally organizing them in a biochemically
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genome-scale reconstruction of numerous metabolic
networks of prokaryotes and eukaryotes [4-6]. In fact, a
genome-scale reconstruction of human metabolism has
been completed, called Recon 1. Recon 1 is a global
human knowledge-base of biochemical transformations
in humans that is not cell or tissue specific [7]. More
recently, Recon 1 has been adapted to study specific
cells and tissues with the help of high-throughput data,
including the human brain [8], liver [9,10], kidney [11],
and alveolar macrophage [12].
Though many cell and tissue-specific models have
been reconstructed from Recon 1, the human erythro-
cyte has undeservedly received less attention as the
cell has been largely assumed to be simple. Histori-
cally, red cell metabolic models began with simple gly-
colytic models [13,14]. In a fifteen year period, the
original mathematical model was updated to include
the pentose phosphate pathway, Rapoport-Luebering
shunt, and adenine nucleotide salvage pathways
[15-18]. More recent metabolic models have been built
accounting for additional regulatory [19] and metabolic
components (e.g. glutathione [20]). However, in the
past decade, attempts to obtain comprehensive proteo-
m i cc o v e r a g eo ft h er e dc e l lh a v ed e m o n s t r a t e da
much richer complement of metabolism than pre-
viously anticipated [21-24]. Modeling the unexpected
complexity of erythrocyte metabolism is critical to
further understanding the red cell and its interactions
with other human cells and tissues.
Thus, we use available proteomics to develop the
largest (in terms of biochemical scope) in silico model
of metabolism of the human red cell to date. Though
comprehensive proteomic data provides an overview
of red cell proteins, we believe it does not provide a
full functional assessment of erythrocyte metabolism.
Thus, we have also gathered 50+ years of erythrocyte
experimental studies in the form of 60+ peer-reviewed
articles and books to manually curate the final model.
In order to objectively test physiological functionality,
we have put the final model through rigorous
simulation.
Results and Discussion
iAB-RBC-283 is a proteomic based metabolic recon-
struction and a biochemical knowledge-base, a func-
tional integration of high-throughput biological data and
existing experimentally verified biochemical erythrocyte
knowledge that can be queried through simulations and
calculations. We first describe the process and charac-
terize the new erythrocyte reconstruction and determine
the metabolic functionality. Then, we analyze the results
by mapping genetic polymorphisms and drug target
information onto the network.
Proteomic based erythrocyte reconstruction
Proteomic data has been successfully used for recon-
structions of Thermotoga maritima [25] and the human
mitochondria [26] and provides direct evidence of a
cell’s ability to carry out specific enzymatic reactions.
One challenge in the measurement of proteomic data is
the depth of coverage, which is still known to be incom-
plete, even for studies aiming to obtain comprehensive
coverage. Another challenge is the possible contamina-
tion in the extract preparation with other blood cells
[21]. In addition, leftover enzymes from immature ery-
throid cells are possibly retained in mature red blood
cells. With multiple comprehensive proteomic studies
carried out in the last decade, the coverage for the red
cell has improved significantly but gaps and inaccurate
data still plague proteomic studies of the erythrocyte.
Thus, in this study, we construct a full bottom-up
reconstruction of erythrocyte metabolism with rigorous
manual curation in which reactions inferred from pro-
teomically detected enzymes were cross-referenced with
existing experimental studies and metabolomic data as
part of the quality control measures to validate and gap
fill metabolic pathways and reactions (Figure 1).
The final reconstruction, iAB-RBC-283, contains a
metabolic network that is much more expansive than
red blood cell models presented to date (Figure 2). The
reconstruction contains 292 intracellular reactions, 77
transporters, 267 unique small metabolites, and accounts
for 283 genes, suggesting that the erythrocyte has a
more varied and expansive metabolic role than pre-
viously recognized.
A full bottom-up reconstruction of the human ery-
throcyte provides a functional interpretation of proteo-
mic data that is biochemically meaningful. Manual
curation provides experimental validation of metabolic
pathways, as well as gap filling. The data can be rigor-
ously and objectively analyzed through in silico
simulation.
Functional assessment of iAB-RBC-283
In order to ascertain the functional capabilities of the
expanded erythrocyte reconstruction, iAB-RBC-283 was
converted into a mathematical model. The expanded
erythrocyte network was topologically and functionally
compared to a previous constraint-based model of ery-
throcyte metabolism [27] (see additional file 1). Predic-
tions made by this model could be recapitulated by iAB-
RBC-283. To determine new functionalities of the
expanded erythrocyte network, the system is assumed to
be at a homeostatic state and qualitative capacity/cap-
ability simulations are done to ascertain which reactions
and pathways can be potentially active in the in silico
erythrocyte. Flux variability analysis (FVA) was utilized
to determine the functional metabolic pathways of the
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determines the minimum and maximum allowable flux
through each metabolic reaction [28]. In short, the FVA
method defines the bounding box on network capabil-
ities. Reactions that had a non-zero minimum or maxi-
mum flux value were deemed to be functional.
Network level metabolic functional assessment showed
that iAB-RBC-283 accounts for additional pathways into
glycolysis through galactose, fructose, mannose, glucosa-
mine, and amino sugars (N-Acetylneuraminate).
Galactose can also be shuttled to the pentose phosphate
pathway through glucuronate interconversions. Citric
acid cycle enzymes (fumarase, isocitrate dehydrogenase,
and malate dehydrogenase) are present, but we were
unable to fully understand their roles as full metabolic
pathways were not present. However, fumarate can be
shuttled into the model and exported as pyruvate
through conversions by fumarase and malic enzyme.
In addition, nucleotide metabolism and salvage path-
ways have been expanded from previous metabolic
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Curated Metabolic Reconstruction
B A
Raw Erythrocyte Proteomic Data
Figure 1 (A) Workflow for building a comprehensive in silico erythrocyte metabolic network. The three major data types required are: the
human genome sequence, high-throughput data (specifically, proteomics for an enucleated cell), and primary literature. The global human
metabolic network, Recon 1, was constructed from the human genome sequence and annotation. To build the erythrocyte network, iAB-RBC-
283, proteomics was used to remove non-erythrocyte related open reading frames (ORFs) or genes. Detailed curation utilizing protein,
metabolite, and transport experimental literature was needed to build a high-quality metabolic reconstruction. (B) Without network
reconstruction and rigorous curation, the experimentally generated proteomic data is raw and difficult to interpret. The process detailed in panel
A provides a means to build a meaningful knowledge-base of available high-throughput data that can then be probed and tested.
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Page 3 of 12models to account for XMP, UMP, GMP, cAMP, and
cGMP metabolism. In particular, ATP and GTP can be
converted into cAMP and cGMP respectively as adeny-
late and guanylate cyclases were found to be present in
the proteomic data.
The erythrocyte uses amino acids to produce glu-
tathione for redox balancing, converts arginine to polya-
mines and a byproduct of urea, and utilizes
homocysteine for methylation. It has been proposed that
Band III is the major methylated protein, particularly for
timing cell death [29]. This has also been included in
iAB-RBC-283. In addition, polyamine metabolism pro-
duces 5-methylthioadenosine which can be salvaged for
methionine recycling.
Another major expansion in metabolic capabilities
represented in iAB-RBC-283 is lipid metabolism.
Though the mature erythrocyte is unable to produce or
degrade fatty acids, the cell can uptake fatty acids from
the blood plasma to produce and incorporate diacyl-
glyercol into phospholipids for upkeep of its membrane
[30]. A pseudo-carnitine shuttle in the cytosol is used to
create a buffer of CoA for the cell [31]. All major ery-
throcyte fatty acids (C16:0, C18:1, C18:2) and phospholi-
pids (phosphatidylcholine, phosphatidylethanolamine,
phosphatidylinositol) are explicitly modeled. The phos-
phatidylinositols can be converted into various forms of
myo-inositols, which play an extensive role in cell sig-
naling [32].
Finally, FVA showed that the erythrocyte plays an
important role in cofactor metabolism. The reconstruc-
tion accounts for uptake, modification, and secretion of
multiple cofactors including vitamin B6, vitamin C,
Figure 2 Topological map of the human erythrocyte metabolic network (iAB-RBC-283). Utilizing proteomic data, a much expanded
metabolic network was reconstructed accounting for additional carbohydrate and nucleotide metabolism. In addition, the erythrocyte plays roles
in amino acid, cofactor, and lipid metabolism. Abbreviations: PPP - pentose phosphate pathway, Arg - arginine, Met - methionine.
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Page 4 of 12riboflavin, thiamine, heme, and NAD. In addition,
human erythrocytes play a role in deactivating catecho-
lamines [33], hydrolyzing leukotriene [34], and detoxify-
ing acetaldehyde [35] which were confirmed in the
literature.
Metabolite connectivity
In order to compare the network structure of the in
silico erythrocyte versus other similar metabolic net-
works, we calculated the connectivity of each metabolite
[36]. Simply, the connectivity is the number of reactions
that a metabolite participates in. As a metabolite can be
defined as a node in a network structure, the biochem-
ical reactions associated with a particular metabolite are
the edges of the network. Metabolite connectivity thus
involves determining the number of edges (reactions)
connected to every node (metabolite).
We compared the in silico erythrocyte to the global
human metabolic network, Recon 1, as well as the sepa-
rate human organelles (Figure 3). A dotted line, linking
the minimum and maximum connectivities, is drawn on
the distributions as a reference for comparing the distri-
butions. A network with higher connectivity would have
many points above the dotted line, while lower connec-
tivity would result in points below the dotted line.
Recon 1 has most points above the reference line (Fig-
ure 3, first panel). In fact, the metabolite node connec-
tivities for genome-scale reconstructions usually have a
distribution similar to Recon 1, highlighting the com-
plexity of these networks [37]. However, the organelles
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Figure 3 The metabolite connectivity of iAB-RBC-283, Recon 1, and the similarly sized organelles in Recon 1. Recon 1 and the
mitochondria have high network connectivity, with many data points above the reference lines. The erythrocyte network and other organelles
have less metabolic connectivity denoted by data point being on or below the reference lines. This characteristic can be attributed to either 1)
an inherently ‘fragmented’ erythrocyte network, or 2) incomplete proteomic coverage.
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due mainly to a higher difficulty to annotate reactions
specific to an organelle. The separate organelle meta-
bolic networks are less connected. The exception is the
mitochondria (Figure 3, last panel), which is well studied
and has a very important and complex metabolic role.
T h em e t a b o l i t ec o n n e c t i v i t yo ft h ee r y t h r o c y t en e t -
work is very similar to the less connected organelles in
Recon 1. This similarity is due to either 1) the erythro-
cyte biology or 2) the lack of complete proteomic profil-
ing. First, as the erythrocyte circulates in blood, it has
access to many types of metabolites. As the erythrocyte
is relatively simple, it is possible that the reconstructed
metabolic network is complete as different types of
metabolites do not have to be created and can easily be
transported into or out of the cell (e.g. amino and fatty
acids). However, the network simplicity of the in silico
erythrocyte model may also be attributed to the limita-
tions of proteomic techniques. As coverage of proteomic
data is typically not as complete as transcriptomics, the
reconstructed metabolic network may reflect this limita-
tion. Thus, deeper proteomic profiling could be of great
use to further elucidate the role of the erythrocyte in
systemic metabolism and the complexity of its own
metabolic network.
In silico simulations show a greater physiological func-
tionality of erythrocyte metabolism. The additional func-
tionality is not evident from the proteomic data alone.
However, metabolite connectivity analysis shows that
additional targeted proteomics are of interest. During
the manual curation steps we noted that portions of the
TCA cycle were detected but not functional. Further
studies for cysteine, folate, and phospholipid metabolism
are also of interest as some enzymes were detected in
the proteomic data but little or no conclusive experi-
mental literature was found.
The human erythrocyte’s potential as a biomarker
Decades of models have described erythrocyte metabo-
lism to include principally glycolysis, the Rapoport-Lue-
bering shunt, the pentose phosphate pathway, and
nucleotide salvage pathways. Integration and compila-
tion of proteomic data, however, has surprisingly shown
evidence of a much richer metabolic role for the ery-
throcyte. Erythrocytes make contact with most portions
of the body and are one of the most abundant cells
(about 2 liters in volume in a typical adult). With such a
varied metabolic capacity, the erythrocyte can act as a
sink for and source of metabolites throughout the body.
Erythrocytes have been previously studied as potential
biomarkers for riboflavin deficiency [38], thiamine defi-
ciency [39], alcoholism [40], diabetes [41], and schizo-
phrenia [42], however comprehensive systems level
analyses have not been performed to date.
iAB-RBC-283 explicitly accounts for the genetic basis
o ft h ee n z y m e sa n dt r a n s p o r t e r st h a ti tr e p r e s e n t s .T o
determine the capability of the in silico erythrocyte as
a potential biomarker, we cross-referenced morbid
SNPs from the OMIM and nearly 4800 drugs from the
DrugBank database with the 281 enzymes accounted
for in iAB-RBC-283. 142 morbid SNPs were found in
90 of the erythrocyte enzymes. In addition, 232 FDA-
approved, FDA-withdrawn, and experimental drugs
have known protein targets in the human erythrocyte
(Figure 4).
Only 35 of the 142 morbid SNPs are related to pathol-
ogies unique to the erythrocyte, mainly dealing with
hemolytic anemia. The majority of the morbid SNPs
deal with pathologies that are peripheral to the red
blood cell and to the blood system. The remaining non-
erythrocyte related pathologies are classified in Table 1
using the Merck Manual [43]. Most of the observed
SNPs are causal and simple targeted assays could be
used as diagnostic tools.
We also cross-referenced the enzymes in iAB-RBC-
283 with the DrugBank’s known protein targets of phar-
maceuticals. 85 FDA-approved, 4 FDA-withdrawn, and
143 experimental drugs have known targets in the
human erythrocyte. These medications target enzymes
for the treatment of a wide range of diseases including
85
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RBC related pathology
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Causal SNPs, Metabolic
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B Drugs with known targets in erythrocyte
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Figure 4 To test the potential use of erythrocytes as
biomarkers, we identified the known morbid SNPs and drug
targets of erythrocyte enzymes account for in the
reconstructed network. 142 morbid SNPs were identified with the
majority dealing with non-erythrocyte related pathologies (see Table
1). In addition, over 230 FDA-approved, FDA-withdrawn, and
experimental drugs have known protein targets in the human
erythrocyte.
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Page 6 of 12seizures (topimarate), allergies (flunisolide), cancer
(topotecan), HIV (saquinavir), and high cholesterol
(gemfibrozil). Due to the availability of erythrocytes
from any individual, drugs can be easily screened and
optimized in vitro for individual patients where the
effect of the drug is known to occur in the erythrocyte.
A comprehensive listing of all observed morbid SNPs
and drugs are provided in the Supplementary Material
(see additional files 2 and 3).
Utilizing iAB-RBC-283 to develop biomarker studies
An important application of metabolic reconstructions
and the resulting mathematical models is to predict and
compare normal and perturbed physiology. We used
iAB-RBC-283 to simulate not only normal conditions to
study the capacity of erythrocyte function, but also the
detected morbid SNPs and drug treated conditions for
drugs with known erythrocyte enzyme targets. Flux
variability analysis was used to characterize the
exchange reactions of the network for determining a
metabolic signature in the erythrocyte for the associated
perturbed conditions. We compared the minimum and
maximum fluxes through each reaction under normal
conditions versus all perturbed conditions and deter-
mined differential reaction activity (see Methods and
Figure 5A). Activated or suppressed flux from in silico
simulations provides a qualitative understanding into
which metabolites and reactions are perturbed, allowing
for experimental followup.
We were able to confidently detect in silico metabolic
flux changes in at least one exchange reaction for 75%
of the morbid SNPs and 70% of the drug treated condi-
tions (Figure 5B). On average, there were 12.6 and 9.9
differential activities of exchange reactions for morbid
SNPs and drug treated conditions respectively. The
average is skewed by some morbid SNPs and drug trea-
ted conditions that have over 45 affected exchange reac-
tions, as most differences are detected in between one
and ten exchange reactions (Figure 5B).
The morbid SNPs with greater than 45 exchange reac-
tions with differential activity deal mostly with glycolytic
and transport enzymes that are known to cause anemias
and spherocytosis (see additional file 2 in Supplementary
Material). In addition, most of the drug treated condi-
tions with high numbers of differential exchange activity
correspond to drugs that have enzyme targets for the
same morbid SNPs that are known to cause hemolytic
diseases.
An important metabolic enzyme found in erythrocytes
is catechol-o-methyltransferase (COMT) used to methy-
late cathecolamines. A morbid SNP of COMT gene has
been implicated in susceptibility to schizophrenia [44].
In silico simulations show that the associated morbid
SNP erythrocyte has lowered uptake of dopamine and
norepinephrine and lowered secretion of the methylated
counterparts. Though COMT has not been shown to be
causal for schizophrenia, the morbid SNP may have an
effect on the phenotype. Qualitative in silico simulation
Table 1 Morbid SNPs with non-erythrocyte related pathologies
Causal SNPs, Metabolic Causal SNPs, Non-Metabolic Correlated SNPs
Pediatric Disorders 28 6 4
Endocrine and Metabolic Disorders 10 2 8
Neurologic Disorders 5 2 1
Genitourinary Disorders 4 2 1
Eye Disorders 1 3 2
Musculoskeletal and Connective Tissue Disorders 3 - 1
None 1 - 3
Gastrointestinal Disorders 1 - 2
Hepatic and Billary Disorders 3 - -
Hematology and Oncology Disorders - - 2
Nutritional Disorders - - 2
Psychiatric Disorders - - 2
Cardiovascular Disorders 1 - -
Dermatologic Disorders - 1 -
Ear, Nose, Throat, and Dental Disorders - 1 -
Immunology, Allergic Disorders 1 - -
Injuries, Poisoning 1 - -
Pulmonary Disorders - - 1
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these metabolic pathways in erythrocyte screening.
In silico simulations show that the erythrocyte can
also be used as a diagnostic for drug treated conditions.
For example, topimarate is a drug for treating seizures
and migraines and inhibits carbonic anhydrase. Inhibi-
tion of this enzyme during simulations showed a drastic
change in 54 exchange reaction fluxes pertaining to car-
bohydrate, cofactor (thiamine, pyridoxine, bilirubin),
lipid, and nucleotide metabolism. As individuals react
differently to pharmaceuticals and sometimes require
different dosages and types of drugs, our analysis shows
that the red blood cell can act as a readily available
diagnostic for personalizing drug therapies.
To further investigate the diagnostic capability of the
red blood cell, we assessed the uniqueness of the meta-
bolic signatures detected. We compared all the metabo-
l i t es i g n a t u r e st os e ei fs o m ew e r es h a r e db e t w e e n
different SNPs or drug treatments. In all, 67% of the
metabolic signatures are unique with most of the
remaining similar to only one other perturbed condition
(Table 2).
The in silico simulation results provide a method to
focus biomarker discovery experiments in the human
erythrocyte, as well as interpret global metabolomic pro-
filing. The flux variability shows that a large number of
morbid SNPs and drug effects can be detected in the
erythrocyte, with most having a unique metabolic signa-
ture. The differential activity in exchanges for the per-
turbed conditions allow for focusing experiments to
particular metabolites, exchanges, and associated path-
ways, allowing development of targeted assays. In addi-
tion, global metabolomic profiling of perturbed
conditions can be interpreted using the calculated meta-
bolic signatures and the erythrocyte reconstruction. A
full listing of all detected morbid SNPs and drug treated
conditions, as well as the corresponding exchange reac-
tions with differential activity and fluxes is provided in
the Supplementary Material (see additional files 2 and
3).
Conclusion
The mature, enucleated erythrocyte is the best studied
human cell for metabolism due to its relative simplicity
and availability. Still, the view of its metabolism is rather
limited. The advances in high-throughput proteomics of
the erythrocyte has enabled construction of a compre-
hensive in silico red blood cell metabolic reconstruction,
iAB-RBC-283. Proteomic data alone is not adequate for
generating an accurate, complete, and functional model.
The reconstruction was rigorously curated and validated
by experimental literature sources as proteomic samples
are known to be incomplete, contaminated with other
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Figure 5 Flux variability of the exchange reactions can be used
to detect metabolic signatures of simulated morbid SNPs and
drug treated erythrocytes. (A) Exchange reactions are artificial
reactions that allow the mathematical model to uptake and secrete
metabolites into the extracellular space. Uptake of a metabolite into
the erythrocyte is expressed as a negative value and secretion is
expressed as a positive value. There are four major differences that
can occur for an exchange reaction in two different states: i) the
reaction is either active (non-zero minimum or maximum flux) or
inactive (zero minimum and maximum flux), ii) the exchange
becomes fixed in one direction (uptake or secretion only), iii) there
is a magnitude change in exchange, iv) the reaction is unaffected
and is the same for both states. (B) We detected 71% and 62% of
the morbid SNPs and drugs associated with the erythrocyte. The
distribution shows that most perturbed conditions have between
one to ten differentially active exchange reactions.
Table 2 Uniqueness of metabolic signatures
# of Metabolic
Signatures
# of conditions sharing same met.
signature
Morbid
SNPs
Drug
Treated
1 (Unique) 19 19
28 3
33 1
41 1
50 1
71 0
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Page 8 of 12types of blood cells and inactive enzymes are passed
down the erythrocyte differentiation lineage. Thus, iAB-
RBC-283 is a knowledge-base of integrated high-
throughput and biological data, which can also be quer-
ied through simulations.
Functional testing showed that the new reconstruction
takes into account historically neglected areas of carbo-
hydrate, amino acid, cofactor, and lipid metabolism.
Traditionally, the erythrocyte is known for its role in
oxygen delivery, but the varied metabolism the cell exhi-
bits points towards a much more expanded metabolic
role as the cell can act as a sink or source of metabo-
lites, through interactions with all organs and tissues in
the body.
Metabolite connectivity analysis showed that the ery-
throcyte metabolic network is relatively simple and is
similar to human organelles in network structure. This
could be due either to shortcomings of the high-
throughput data or the relatively simple metabolism of
red cells. From our manual curation steps, targeted pro-
teomic studies would be useful for a few metabolic path-
ways: including TCA cycle, cysteine, folate, and
phospholipid metabolism.
A metabolically rich and readily available erythrocyte
can be useful for clinical biomarkers. To determine
potential uses, we cross-referenced the enzymes in iAB-
RBC-283 with known morbid SNPs and enzymes that
are reported drug targets in DrugBank. There are 142
morbid SNPs detectable in erythrocyte enzymes with
the majority dealing with non-erythrocyte related
pathologies. In addition, over 230 pharmaceuticals in
the DrugBank have known protein targets in the human
erythrocyte.
Utilizing iAB-RBC-283, we qualitatively detected
metabolic signatures for the majority of in silico per-
turbed conditions pertaining to the morbid SNPs and
drugs from DrugBank. The affected exchange reactions,
metabolites, and associated pathways can be used to
focus experiments for biomarker discovery as well as
interpret global metabolomic profiles.
Taken together, with available proteomic data, a
comprehensive constraint-based model of erythrocyte
metabolism was developed. Genome-scale metabolic
reconstructions have been shown to be an important tool
for integrating and analyzing high-throughput data for
biological insight [8,12,45,46]. In this study, we show that
the comprehensive metabolic network of the erythrocyte
plays an unanticipated, varied metabolic role in human
physiology and thus has much potential as a biomarker
with clinical applications. As erythrocytes are readily avail-
able, the proteomics and metabolomics of normal and
pathological states of individuals can be easily obtained
and used for identifying biomarkers in a systems context.
Methods
Reconstructing the comprehensive erythrocyte network
Metabolic network reconstruction has matured into a
methodological, systematic process with quality control
and quality assurance steps that can be carried out
according to standardized detailed protocols [3]. The
sequencing of the human genome enabled a comprehen-
sive, global reconstruction for all human cell types to be
carried out, with the caveat that in order to implement
any context, condition, or cell specific analysis, one
would need specific data for the particular human cell
or tissue of interest.
Metabolic reconstructions contain all known meta-
bolic reactions of a particular system. The reactions are
charge and elementally balanced, with gene-protein-
reaction (GPR) annotations. GPRs mechanistically con-
nect the genome sequence with the proteome and the
enzymatic reactions. GPRs provide a platform for inte-
gration of high-throughput data to model specific condi-
tions. In this study, proteomic data was integrated with
Recon 1 to build a comprehensive erythrocyte network.
iAB-RBC-283 was reconstructed in the following man-
ner. Proteomic data for erythrocytes from multiple
sources [21-24] were consolidated and cross-referenced
with Recon 1. The proteomic data was provided in the
IPI format and was converted to Entrez Gene Ids. The
Entrez Ids were linked with the Recon 1 transcripts,
including alternatively spliced variants, and used to gen-
erate a list of potential erythrocyte reactions. Reactions
and pathways from Recon 1 that were present in the
proteomic data were used to build an automated draft
reconstruction. However, blood cell contamination and
remnant enzymes from immature erythroid cells
decrease the accuracy of algorithmically derived models
based on high-throughput data. In order to build the
most complete and accurate final model, the draft
reconstruction was rigorously and iteratively manually
curated. In brief, manual curation involves (1) resolving
all metabolite, reaction, and enzyme promiscuity, (2)
exploring existing experimental literature to determine
whether or not detected enzymes in the proteomics data
are correct, (3) determining and filling gaps in the pro-
teomic data through topological gap analysis and flux-
based functional tests. Steps 2 and 3 are an iterative
process where new biochemical data increases the scope
of the network, requiring additional gap and functional
analysis as well as additional literature mining.
Thus, possible remnant enzymes, such as glycogen
synthase and aspartate aminotransferase, were properly
removed when experimental validation was not avail-
able. The manual curation process yielded 60+ peer
reviewed articles and books representing over 50 years
of erythrocyte research. In addition, erythrocyte
Bordbar et al. BMC Systems Biology 2011, 5:110
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base [47] were used for validating existence of unique
metabolites. A full listing of literature sources for each
reaction, enzyme, and metabolite is provided in the Sup-
plementary Material (see additional file 4, iAB-RBC-283
in XLS format).
Fatty acid chains were not represented as generic R-
groups as in Recon 1, but instead the three most com-
mon (by percent mass composition) fatty acids, palmitic,
linolenic, and linoleic (C16:0, C18:1, C18:2, respectively)
were used [48]. The final reconstruction is termed iAB-
RBC-283 for i (in silico), AB (the primary author’s initi-
als), RBC (red blood cell), 283 (number of open reading
frames accounted for in the network). iAB-RBC-283
consists of all the known metabolites, reactions, thermo-
dynamic directionality, and genetic information that the
detected erythrocyte metabolic enzymes catalyze. The
final reconstruction is provided in both an XLS and
SBML format in the Supplementary Material (additional
files 4 and 5) and can also be found at the BioModels
Database (id: MODEL1106080000).
Constraint-based modeling and functional testing
The network reconstruction can be represented as a
stoichiometric matrix, S,t h a ti sf o r m e df r o mt h es t o i -
chiometric coefficients of the biochemical transforma-
tions. Each column of the matrix represents a particular
elementally and charge balanced reaction in the net-
work, while each row corresponds to a particular meta-
bolite [37]. Thus, the stoichiometric matrix converts the
individual fluxes into network based time derivatives of
the concentrations (Equation 1).
dx
dt
= S · v (1)
As each reaction is comprised of only a few metabo-
lites, but there are many metabolites in a network, each
flux vector is quite sparse. The stoichiometric matrix is
sparse, with 1.3% non-zero elements, and has dimen-
sions (m × n); where m is the number of compounds
and n is the number of reactions. In the case of iAB-
RBC-283, m is 342 and n is 469.
As in vivo kinetic parameters are difficult to obtain,
the system is assumed to be at a homeostatic state
(Equation 2),
S · v = 0 (2)
allowing for simulation without kinetic parameters.
The network fluxes (v) are bounded by thermodynamic
constraints that limit the directionality of irreversible
catalytic mechanisms (lb = 0 for irreversible reactions)
as well as known vmax’s.
lb < v < ub (3)
Thus, the network is studied under mass conservation
and thermodynamic constraints. In addition, constraints
are placed on fluxes that exchange metabolites with the
surrounding system (the blood plasma in this case),
based on existing literature of metabolite transport in
the human erythrocyte (see additional file 6 in Supple-
mentary Material). These reactions are called exchange
reactions and control the flow of metabolites into and
out of the in silico cell.
Flux balance analysis (FBA) is a well-established opti-
mization procedure [37] used to determine the maxi-
mum possible flux through a particular reaction in the
network based on the constraints on the network (Equa-
t i o n s2a n d3 )w i t h o u tt h en e e df o rk i n e t i cp a r a m e t e r s .
A primer for using FBA and related tools is detailed by
Orth et al. [49]. Publicly available software packages
exist [50]
In this work, a variant of FBA, called flux variability
analysis (FVA) [28], is used. FVA iteratively calculates
both the maximum and minimum allowable flux
through every reaction in the network. Reactions with a
calculated non-zero maximum or minimum have the
potential to be active and have a potential physiological
function. Thus, we use FVA to determine the capability/
capacity of the network reactions to determine meta-
bolic functionality. For a reaction to have a non-zero
flux, the reaction must be linked to other metabolic
reactions and pathways and plays a functional role in
the system. Thus, potentially active reactions are
deemed as functional. After determining which reactions
were functional, the reaction list was perused to deter-
mine pathway and subsystem functionality in the
network.
Calculating metabolite connectivity
The stoichiometric matrices of the reconstructed ery-
throcyte network, Recon 1, and its constituent orga-
nelles were used to calculate metabolite connectivities
[36] of every species in each network. The number of
reactions each metabolite participates in was summed.
For the organelle calculations, only the metabolites cor-
responding to the particular organelle of Recon 1 were
considered. The metabolite connectivity of each orga-
nelle as well as Recon 1 and iAB-RBC-283 was ranked
order from greatest to least connected to form a discrete
distribution (Figure 3).
Analyzing iAB-RBC-283 as a functional biomarker
The Morbid Map from the Online Mendelian Inheri-
tance in Man (OMIM) [51] and the DrugBank [52] were
downloaded from their respective databases (accession
Bordbar et al. BMC Systems Biology 2011, 5:110
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were cross-referenced against the database entries to
determine morbid SNPs in erythrocyte proteins and
drugs with protein targets in the erythrocyte. The mor-
b i dS N P st h a td i dn o th a v es o l ep a t h o l o g i c a le f f e c t si n
the erythrocyte were classified using the Merck Manual
[43].
Just as FVA can be used to assess the function of a
network under a particular set of constraints, it can also
be used to assess the changes in function and thus has
applications for characterizing disease states [53] and
identifying biomarkers [54]. When simulating a morbid
SNP or a drug inhibited enzyme, the lower and upper
bound constraints on the affected reaction is set to zero
as per Shlomi et al. FVA is then used to characterize
the exchange reactions under morbid SNP or drug trea-
ted conditions (Figure 5A) and then compared to the
normal state. A reaction was considered to be confi-
dently altered if the change in the minimum or maxi-
mum flux was 40% of the total flux span. The flux span
is defined as the absolute difference between the original
(unperturbed) maximum and minimum fluxes. Potential
thresholds from 5 - 60% were tested. Thresholds in the
15 - 40% range were very consistent while thresholds
above 40% had a dropoff (see additional file 7).
Additional material
Additional file 1: Comparison of iAB-RBC-283 and previous
constraint-based model of human erythrocyte. iAB-RBC-283 was
compared with the previous constraint-based model of the human
erythrocyte. Topological analysis showed that iAB-RBC-283 is a much
more expansive network that better describes human erythrocyte
metabolism. In addition, we recapitulated the randomized sampling
results of the previous network and showed that the new erythrocyte
model is more accurate, capturing all the correct predictions of the
previous model but also correcting its inaccurate predictions.
Additional file 2: Detected SNPs and FVA results for SNP
perturbations. Tables containing the OMIM SNPs of enzymes that are in
iAB-RBC-283 with known pathologies, symptoms, metabolic subsystem,
and classification. In addition, exchange reactions determined by FVA to
be different in SNP perturbations are provided.
Additional file 3: Detected drug targets and FVA results for drug
effect perturbations. Tables containing the known drugs, from
DrugBank, that have targets in enzymes that are in iAB-RBC-283. In
addition, information is provided on the drug including name,
description, and classification. The exchange reactions determined by
FVA to be different in drug perturbations are also provided.
Additional file 4: iAB-RBC-283 Reconstruction (table format). The
reconstruction is provided in a table format with reactions, metabolites,
and gene-protein-reaction associations. In addition, information is
provided on whether the reaction was detected in the proteomic or
metabolomic data and citations are provided for reactions with existing
experimental evidence, implicating the reactions presence in the human
erythrocyte.
Additional file 5: iAB-RBC-283 Reconstruction (SBML format). The
reconstruction is provided in the standardized SBML format. The XML file
can be loaded in to COBRA toolbox to perform in silico simulations. A
copy of the file is also available at the BioModels Database (id:
MODEL1106080000).
Additional file 6: Citations for exchanges in the human erythrocyte.
Table containing citations used to determine exchange rates of
metabolites into the human erythrocyte.
Additional file 7: Parameter sensitivity of threshold for FVA
simulations. Figure showing the average number of FVA-detected
exchange reactions for each perturbation and different thresholds.
Thresholds were tested from 5-60% at intervals of 5%. The average
detected reactions were quite stable from 15-40% for both the SNP and
drug perturbations. A final 40% threshold was used in the study.
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